DiaPep 277
- Generic Name
- DiaPep 277
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C106H180N28O34
- CAS Number
- 179822-83-4
- Unique Ingredient Identifier
- F8778UWB0A
- Background
DiaPep 277 is a 24-mer laboratory-made peptide derived from Hsp60(437-460).
- Indication
Investigated for use/treatment in diabetes mellitus type 1, autoimmune diseases, and diabetes mellitus type 2.
- Associated Conditions
- -
- Associated Therapies
- -
OPen Label Study to Evaluate Long Term Treatment Effect of DiaPep277
- First Posted Date
- 2011-10-26
- Last Posted Date
- 2015-03-19
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 11
- Registration Number
- NCT01460251
- Locations
- ๐ฎ๐ฑ
Hadassah Medical Center, Jerusalem, Israel
๐ฎ๐ฑSchneider Children's Medical Center, Petah-Tikva, Israel
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
- First Posted Date
- 2010-04-14
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Andromeda Biotech Ltd.
- Target Recruit Count
- 475
- Registration Number
- NCT01103284
- Locations
- ๐บ๐ธ
AM Diabetes & Endocrinology Center, Bartlett, Tennessee, United States
๐บ๐ธSutter Gold Medical Foundation, Modesto, California, United States
๐บ๐ธSan Diego Clinical Trials, San Diego, California, United States
Long-Term Treatment Effect of DiaPep277 in Type 1 Diabetes
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2013-07-11
- Lead Sponsor
- Andromeda Biotech Ltd.
- Target Recruit Count
- 43
- Registration Number
- NCT00644501
- Locations
- ๐ฎ๐ฑ
Diabetic Unit, Hadassah Medical Center, Jerusalem, Israel
๐ฎ๐ฑSchneider Children's Medical Centre, Petach Tikva, Israel
๐ฎ๐ฑWolfson Medical Centre, Holon, Israel
Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2016-06-06
- Lead Sponsor
- Andromeda Biotech Ltd.
- Target Recruit Count
- 457
- Registration Number
- NCT00615264
- Locations
- ๐จ๐ฟ
Faculty hospital Motol., Prague, Czech Republic
๐ฎ๐ฑSchneider Children's Medical Centre, Petach Tikva, Israel
๐ฎ๐นUniversita' degli Studi di Bari, Bari, Italy
Safety, Tolerability, Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in Latent Autoimmune Diabetes in Adults (LADA)
- Conditions
- First Posted Date
- 2003-04-24
- Last Posted Date
- 2009-03-19
- Lead Sponsor
- DeveloGen Israel, Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT00058981
- Locations
- ๐บ๐ธ
University of Colorado Hospital Endocrinology Practice, Aurora, Colorado, United States
๐บ๐ธUniversity of Alabama at Birmingham Endocrinology Department, Birmingham, Alabama, United States
๐บ๐ธUniversity of Kentucky Department of Internal Medicine, Lexington, Kentucky, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.